Efficacy of submucosal injection of hyaluronidase after mandibular third molar surgery: a randomized controlled trial
10.5125/jkaoms.2022.48.6.363
- Author:
Sanghoon LEE
1
;
Hyounmin KIM
;
Woong NAM
Author Information
1. Department of Oral and Maxillofacial Surgery, Yonsei University College of Dentistry, Seoul, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2022;48(6):363-370
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:This study aimed to investigate the efficacy of postoperative submucosal injection of hyaluronidase (HUD) for reducing sequelae andquality of life (QOL) after mandibular third molar (M3M) surgery.
Materials and Methods:Participants with bilateral impacted M3M underwent surgical extraction with a split-mouth randomized controlled studydesign. M3M were removed by the same surgeon in 2 sessions, one a control and the other experimental. Submucosal injection of HUD was performedin the experimental session and submucosal injection of saline in the control session. Mouth opening, facial swelling, and pain intensity were measured before surgery, and then 2 and 7 days after surgery. The QOL of participants following surgery was evaluated by means of a patient-centered outcome questionnaire (PCOQ).
Results:A total of 36 patients was included in the final data analysis. There was a significant reduction in the maximal mouth opening and postoperative pain in the experimental side at the 2 and 7 days after surgery (P<0.05), and a remarkable difference in facial swelling was reported on the experimental side 7 days after surgery (P<0.05). The PCOQ demonstrated that participants reported less pain and swelling on the experimental side.
Conclusion:The present study provides clinical evidence that submucosal administration of HUD immediately after M3M surgery reduced postop-erative discomfort and improved patients’ QOL.
